What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Cigna's Evernorth to Remove Prior Authorization for BrainsWay TMS Treatments

Evernorth Behavioral Health, a division of the Cigna Group, has announced the removal of prior authorization requirements for Transcranial Magnetic Stimulation (TMS) therapy. This strategic policy change is set to take effect on March 6, 2026, and will cover more than 18 million beneficiaries across 12 states. BrainsWay, a global leader in noninvasive brain stimulation technologies, stands to benefit significantly from this reduction in administrative hurdles. The move aims to streamline access to mental health care and accelerate the time between clinical diagnosis and the commencement of treatment. Analysts view this development as a major bullish catalyst for BrainsWay, as it facilitates broader market penetration in the U.S. healthcare sector. By eliminating insurance barriers, the company is expected to see a substantial increase in the adoption of its advanced medical technology and overall revenue growth.

Cigna's Evernorth to Remove Prior Authorization for BrainsWay TMS Treatments

Instruments